{"groups":[{"description":"Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.","id":"FG000","title":"Dabrafenib and Trametinib Combination Therapy"},{"description":"Subjects received matching placebos orally for 12 months","id":"FG001","title":"Dabrafenib and Trametinib Placebos"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"125"},{"groupId":"FG001","numSubjects":"136"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"225"},{"groupId":"FG001","numSubjects":"192"}],"type":"Study closed by sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"43"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"8"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"50"},{"groupId":"FG001","numSubjects":"53"}],"type":"Withdrawal by Subject"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"438"},{"groupId":"FG001","numSubjects":"432"}],"comment":"All randomized patients are included in the Intent-to-Treat Population (ITT) regardless of whether or not they received study treatment.","type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"}],"type":"Untreated"},{"achievements":[{"groupId":"FG000","numSubjects":"435"},{"groupId":"FG001","numSubjects":"432"}],"comment":"All patients who received at least one dose of randomized treatment.","type":"Safety Population"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"438"},{"groupId":"FG001","numSubjects":"432"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients were planned to be randomized in a 1:1 ratio, stratified by BRAF mutation status (V600E, V600K) and stage of disease (Stage IIIa, IIIb, IIIc).","recruitmentDetails":"The study was conducted in 169 centers across 25 countries."}